KRT82

Across TCGA pan-cancer cohorts, KRT82 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRT82 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher KRT82 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRT82 expression acts as an unfavorable survival marker.

KIRC, LIHC, and SKCM are the cancer types where KRT82 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	II,III,IV	0.134	0.717	.018	18	view →
LIHC	DFS	Median	All	0.046	0.553	<.001	18	view →
SKCM	OS	Median	II,III,IV	0.352	0.740	.007	10	view →
LUSC	OS	Median	II,III,IV	0.173	0.677	.029	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KRT82–KIRC (OS)

Open the KIRC breakdown →